Bridging pharmacokinetics study of XRx-008 for autosomal dominant polycystic kidney disease

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Apr 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oxipurinol (Primary)
Indications Acute kidney injury; Acute lung injury; Autosomal dominant polycystic kidney disease
Focus Pharmacokinetics

21 Apr 2023 According to XORTX media release, company is looking forward to our upcoming meeting with the FDA on May 1, 2023 to discuss our planned phase 3 clinical program for XORLO.
19 Jan 2023 Results presented in a XORTX Therapeutics Media Release.
19 Dec 2022 According to a XORTX Therapeutics media release, Plasma sample analysis and topline results from both part 3 and part 4 are expected within the next several weeks. Consolidated topline results from each part are anticipated to be reported in January 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com